TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Prime Medicine, Inc. ( (PRME) ).
On August 1, 2025, Prime Medicine, Inc. held a special virtual meeting of stockholders to vote on key proposals. The company’s stockholders approved the Option Repricing Proposal and an Adjournment Proposal, although the latter was deemed unnecessary due to sufficient quorum and proxy votes.
The most recent analyst rating on (PRME) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Prime Medicine, Inc. stock, see the PRME Stock Forecast page.
Spark’s Take on PRME Stock
According to Spark, TipRanks’ AI Analyst, PRME is a Neutral.
Prime Medicine, Inc. faces significant financial hurdles with ongoing losses and dependency on external funding. While recent technical indicators show potential for recovery, the stock remains under pressure. The promising preclinical results offer a positive long-term outlook, but the current valuation and financial performance weigh heavily on the overall score.
To see Spark’s full report on PRME stock, click here.
More about Prime Medicine, Inc.
Average Trading Volume: 3,877,635
Technical Sentiment Signal: Buy
Current Market Cap: $543.4M
For detailed information about PRME stock, go to TipRanks’ Stock Analysis page.